FDA adds pembrolizumab-chemo nod for biliary tract cancer; prior RCC, TMB-H actions standNov 10Regulatory decisionbelzutifanMerck & Co., Inc.Updated
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Merck posts Q3 2026 results with oncology approvals and new sac-TMT regulatory filingOct 29Quarterly updateGilead SciencesMerck & Co., Inc.
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
FDA clears efficacy supplement for Merck's Keytruda QlexOct 22Regulatory decisionMerck & Co., Inc.pembrolizumab and berahyaluronidase alfa-pmph
Merck posts Q2 loss on Terns charge, raises full-year sales outlookAug 4Quarterly updateMerck & Co., Inc.
Gilead reports Q2 2026 results with three FDA approvals, three positive Phase 3 readoutsAug 4Quarterly updateGilead Sciences